Aurora Investment Counsel Makes New Investment in Integer Holdings Corporation $ITGR

Aurora Investment Counsel bought a new stake in shares of Integer Holdings Corporation (NYSE:ITGR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 14,671 shares of the medical equipment provider’s stock, valued at approximately $1,804,000.

Several other institutional investors have also bought and sold shares of the business. Intech Investment Management LLC boosted its position in shares of Integer by 92.8% during the first quarter. Intech Investment Management LLC now owns 22,682 shares of the medical equipment provider’s stock valued at $2,677,000 after buying an additional 10,915 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Integer in the 1st quarter valued at about $916,000. Russell Investments Group Ltd. grew its position in shares of Integer by 14.7% in the 1st quarter. Russell Investments Group Ltd. now owns 6,749 shares of the medical equipment provider’s stock worth $796,000 after buying an additional 863 shares during the last quarter. Aberdeen Group plc raised its stake in shares of Integer by 38.5% during the 2nd quarter. Aberdeen Group plc now owns 319,229 shares of the medical equipment provider’s stock worth $39,256,000 after acquiring an additional 88,784 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in Integer during the first quarter valued at approximately $579,000. Institutional investors own 99.29% of the company’s stock.

Integer Stock Up 2.4%

Shares of NYSE ITGR opened at $107.38 on Tuesday. Integer Holdings Corporation has a 12-month low of $99.54 and a 12-month high of $146.36. The stock has a market cap of $3.76 billion, a PE ratio of 47.30, a P/E/G ratio of 0.83 and a beta of 0.97. The company has a current ratio of 3.41, a quick ratio of 2.18 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average of $104.95 and a 200 day moving average of $113.00.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The company had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. During the same period last year, the firm posted $1.30 EPS. The business’s quarterly revenue was up 11.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, sell-side analysts predict that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ITGR shares. Truist Financial dropped their target price on shares of Integer from $137.00 to $121.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research note on Wednesday, October 8th. Wells Fargo & Company lowered their price target on shares of Integer from $152.00 to $132.00 and set an “overweight” rating on the stock in a report on Friday, July 25th. Wall Street Zen upgraded shares of Integer from a “hold” rating to a “buy” rating in a research report on Saturday, August 30th. Finally, Raymond James Financial cut their price objective on shares of Integer from $150.00 to $143.00 and set an “outperform” rating for the company in a report on Friday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.29.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.